borderline significantp = 0.05
Moreover, in a prospective randomized, double-blind, placebo-controlled trial enrolling 106 patients with both NAFLD and T2DM who were assigned to receive empagliflozin 10 mg ( n = 35), pioglitazone 30 mg ( n = 34), or placebo ( n = 37) for 24 weeks, only a borderline significant decrease in CAP score was observed with empagliflozin compared with placebo (−29.6 dB/m (−39.5 to −19.6) vs. −16.4 dB/m (−25.0 to −7.8), respectively; p = 0.05) [ 39 ].